| hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3-Erk1/2 Signaling Pathway. | hMAGEA2 Accelerates the Progression of Prostate Cancer via the EFNA3-Erk1/2 Signaling Pathway.
Han S, Jang S, Lee SW, Kim HY, Kim W, Kim HG, Park JK, Han JE, Ryoo ZY, Seah E, Kim C, Lee J, Park S, Choi SK. | 07/16/2024 |
| Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression. | Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.
Saeednejad Zanjani L, Razmi M, Fattahi F, Kalantari E, Abolhasani M, Saki S, Madjd Z, Mohsenzadegan M. | 03/12/2022 |
| Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis. | Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis.
Khalvandi A, Abolhasani M, Madjd Z, Sharifi L, Bakhshi P, Mohsenzadegan M. | 09/18/2021 |
| high MAGEA2 expression is an independent prognostic factor for glioma patient poor overall survival | Melanoma-associated antigen A2 is overexpressed in glioma and associated with poor prognosis in glioma patients.
Meng Q, Luo G, Liu B, Sun Y, Yan Z. | 07/6/2019 |
| Data indicate that melanoma-associated antigen A2 (MAGEA2)is significantly overexpressed in triple-negative breast cancer (TNBC) tissues and is important for progression of TNBC and may serve as a novel molecular therapeutic target. | hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways.
Park S, Sung Y, Jeong J, Choi M, Lee J, Kwon W, Jang S, Park SJ, Kim HS, Lee MH, Kim DJ, Liu K, Kim SH, Dong Z, Ryoo ZY, Kim MO., Free PMC Article | 03/24/2018 |
| suppression of MAGEA2 in lung cancer cells significantly reduced the growth/survival of cancer cells. High-MAGEA2 was identified as an independent prognostic factor in lung adenocarcinoma. Specific inhibition of MAGEA2 may be a promising therapeutic strategy for patients with lung cancer. | Overexpression of MAGEA2 has a prognostic significance and is a potential therapeutic target for patients with lung cancer.
Ujiie H, Kato T, Lee D, Hu HP, Fujino K, Kaji M, Kaga K, Matsui Y, Yasufuku K. | 03/3/2018 |
| Immunohistochemistry using D2-40 monoclonal antibody (MAGE2) and anti-MITF1 increased detection of lymphovascular invasion in primary cutaneous melanoma. | Prognostic Implication of Lymphovascular Invasion Detected by Double Immunostaining for D2-40 and MITF1 in Primary Cutaneous Melanoma.
Feldmeyer L, Tetzlaff M, Fox P, Nagarajan P, Curry J, Ivan D, Torres Cabala CA, Prieto VG, Aung PP. | 01/28/2017 |
| We find that MAGE-A2 interacts with MDM2 via the N-terminal p53-binding pocket and the RING finger domain of MDM2 that is required for homo/hetero-dimerization and for E2 ligase interaction. | MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
Marcar L, Ihrig B, Hourihan J, Bray SE, Quinlan PR, Jordan LB, Thompson AM, Hupp TR, Meek DW., Free PMC Article | 04/23/2016 |
| Consistent with increased cell death, the induced loss of MAGEA2 expression correlated with increased caspase 3/7 activity, BCL2/BAX ratio and TUNEL signal. | The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Zeng L, Kang C, Di C, Fee BE, Rivas M, Lin J, Adamson DC. | 11/29/2014 |
| MAGEA2 has a critical role in the development of tamoxifen-resistant breast cancer | Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer.
Wong PP, Yeoh CC, Ahmad AS, Chelala C, Gillett C, Speirs V, Jones JL, Hurst HC., Free PMC Article | 11/22/2014 |
| MageA2 interferes with p53 acetylation at PML-nuclear bodies (NBs) and with PMLIV-dependent activation of p53. | MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
Peche LY, Scolz M, Ladelfa MF, Monte M, Schneider C., Free PMC Article | 09/15/2012 |
| Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells. | MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases.
Shin KC, Lee KH, Lee CH, Shin IH, Suh HS, Jeon CH., Free PMC Article | 06/2/2012 |
| These data suggest that MAGEA2 is differentially expressed in HNSCC and functions, in part, through the p53 pathway by increasing cellular proliferation and abrogating cell cycle arrest. | The role of MAGEA2 in head and neck cancer.
Glazer CA, Smith IM, Bhan S, Sun W, Chang SS, Pattani KM, Westra W, Khan Z, Califano JA., Free PMC Article | 05/28/2011 |
| Multiple simultaneous detection of MAGE-A [subtypes] more specific and sensitive than detection of single MAGE-A antigen for the diagnostic and prognostic evaluation of oral squamous cell carcinoma | Expression of melanoma-associated antigens in oral squamous cell carcinoma.
Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW, Nkenke E. | 01/21/2010 |
| These data show, for the first time, the involvement of methyl-CpG binding domain proteins in the regulation of the MAGE-A genes. | Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F, Friese O, Pantel K, Schwarzenbach H. | 01/21/2010 |
| MAGE-A2 targets p53 transactivation function through histone deacetylase recruitment | MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C., Free PMC Article | 01/21/2010 |